Clinical Trial Update: Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating olaparib monotherapy in relapsed small cell lung cancer patients with HR pathway gene mutations beyond BRCA1/2, ATM deficiency, or MRE1…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Olaparib (Olaparib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Small Cell Lung Cancer | Phase 2 | Status: COMPLETED